Panel Disdussion

3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of
Congress of Nuclear Medicine
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011
Development of an in vivo radionuclide generator by labeling
Bleomycin with 191Os
Leila Moghaddam-Banaem 1 , Amir Reza Jalilian 1 , Mina Jamreh 2 ,
Nafiseh Salek 2 , Mojtaba Shamsaee 2
1 Radiopharmaceutical Research and Development Lab (RRDL)
2 Faculty of Nuclear Engineering and Physics-AmirKabir Technical University
Bleomycin (BLM) has been labeled with various radioisotopes and
widely used in therapy and diagnosis. 191Osmium is a parent
radionuclide with 15.4d half-life and decays by beta emission to
191mIridium which is a radionuclide with 4.96s half-life. It decays by
isometric transition to stable 191Ir, emitting a 129-keV gamma
photon. In this study BLM was labeled with 191Os-hexachloro-osmate
and its distribution and stability in mice was determined. The
complex was obtained at the pH=2 in normal saline at 90°C in 60
minutes. Radio-TLC showed an overall radiochemical yield of 95-97%
(radiochemical purity >97%). The biodistribution studies for 191Os
and 191Os -BLM were carried out in mice up to 15d. Liver and spleen
uptake increased 24-48 hours after administration of 191Os-BLM.
Lung uptake increased after 48 hours. Twenty four hours after
administration, the radioactivity of the bladder and kidney increased
and remained constant. This research introduces 191Os-BLM in
therapeutic studies as an in-vivo generator for therapy because of
beta emissions and also for localization and dosimetry study in
relevant organs by gamma emission of the daughter radio-nuclide.
Keywords: 191Osmium-Bleomycin, Labeling, Biodistribution
159